Dr. Mandler, molecular biologist by training, is founder and CEO of Tridem Bioscience, bringing with him over 15 years of collaborative research and management experience in academia and industry
Dr. Mandler is the former CSO of Accanis Biotech. Prior to that he served as head of the Neurodegeneration Department at AFFiRiS AG where he was developing the vaccine portfolio for the treatment of neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease and multisystem atrophy. In this position he was responsible for preclinical development of the first two peptide-based vaccines ever tested in humans for Parkinson’s disease and multisystem atrophy.
He has authored 20 publications in high impact journals and more than 25 patents and patent applications and has received multiple national and international research grants for his work
